Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIRVANA: Nivolumab + Radiotherapy in Advanced Melanoma
NCT02799901Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Mar 2017
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in melanoma, sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Overall Survival at 1 year. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02799901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02799901.